Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective, double-blind, placebo-controlled, randomized, multi-center trial of NT 201 (Xeomin) for post-stroke upper limb spasticity
2005-003951-11Phase 3Completed
- Sponsor
- Merz
- Start
- Dec 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in poststroke spasticity (PSS) and Muscle spasm comparing NT 201 (Xeomin) with Placebo (2 arms). Primary endpoint: Primary endpoint: responder analysis at week 4 (V4). Started Dec 2005; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
poststroke spasticity (PSS)Muscle spasm
Beyond the preview
Go deeper on 2005-003951-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003951-11.